ライフサイエンスコーパス: serous carcinoma

1 clusion cysts to a conventional (high-grade) serous carcinoma.

2 53 allele occurs early in the development of serous carcinoma.

3 ivity to chemotherapy relative to high-grade serous carcinoma.

4 option for patients with recurrent low-grade serous carcinoma.

5 of care in patients with recurrent low-grade serous carcinoma.

6 n A1 mRNA levels in patients with high-grade serous carcinoma.

7 rotransposition events in high-grade ovarian serous carcinoma.

8 shows prognostic significance for high-grade serous carcinoma.

9 tions for mucinous, clear-cell, or low-grade serous carcinoma.

10 irror those of human tubo-ovarian high-grade serous carcinoma.

11 cer, including the highly aggressive ovarian serous carcinoma.

12 way activation have been reported in ovarian serous carcinoma.

13 greater GC UNC-45 expression than low-stage serous carcinoma.

14 p13.12 in 6 of 31 (19.5%) ovarian high-grade serous carcinomas.

15 s to noninvasive and invasive micropapillary serous carcinomas.

16 tage serous BOTs and later developed grade 1 serous carcinomas.

17 OR = 1.22, 95 %CI = 0.97-1.53) in high grade serous carcinomas.

18 ates than cell lines derived from high-grade serous carcinomas.

19 hways through profiling of normal FTSECs and serous carcinomas.

20 type II OvCAs, most of which are high-grade serous carcinomas.

21 er was significantly higher in HG than in LG serous carcinomas.

22 vely, in independent 47 affinity-purified HG serous carcinomas.

23 oved disease-specific survival in high-grade serous carcinoma (0.71, 0.55-0.91; p=0.0080), but weak P

24 n cancer were included: 1742 with high-grade serous carcinoma, 110 with low-grade serous carcinoma, 2

25 , 1073 (69%) of 1566 patients had high-grade serous carcinoma, 1119 (71%) had stage IIIC-IV disease,

26 rcinomas (6.7%) and 5 of 26 type II uterine (serous) carcinomas (19.2%).

27 h-grade serous carcinoma, 110 with low-grade serous carcinoma, 207 with mucinous carcinoma, 484 with

28 s borderline tumors, but among the low-grade serous carcinomas (39 stage III, 2 stage II, and 2 stage

29 R-2 expression and amplification was seen in serous carcinoma (43% and 29%), while grade 1 endometrio

30 Thirty-four uterine serous carcinomas, a type of endometrial carcinoma with

31 High-grade serous carcinoma, accounts for up to 70% of all ovarian

32 33-0.90), which was similar among high grade serous carcinomas, although not statistically significan

33 ive histological subtypes (uterine papillary serous carcinoma and clear cell carcinoma, UPSC/CCC) by

34 d 18 years or older with recurrent low-grade serous carcinoma and measurable disease, as defined by R

35 the majority representing uterine papillary serous carcinoma and mixed malignant mesodermal tumor.

36 a demonstrate that MI is uncommon in uterine serous carcinoma and support that different pathogenetic

37 Women age < 35 years with low-grade serous carcinoma and those with persistent disease at co

38 ian tumors (BOT) can progress into low-grade serous carcinomas and have relatively indolent clinical

39 except frequent p53 mutations in high-grade serous carcinomas and malignant mixed mesodermal tumors

40 fimbria as a field of origin for high-grade serous carcinomas and present a binary model of ovarian

41 -1 is significantly overexpressed in ovarian serous carcinomas and several other types of carcinomas.

42 m a primary tumour (mesothelioma, peritoneal serous carcinoma) and other times arising from a metasta

43 arian neoplastic lesions, especially uterine serous carcinomas, and suggest that mutation of PPP2R1A

44 , and seromucinous carcinomas; ii) low-grade serous carcinomas; and iii) mucinous carcinomas and mali

45 ate that the precursor of ovarian high-grade serous carcinoma appears to develop from an occult intra

46 Low-grade ovarian serous carcinomas are believed to arise via an adenoma-s

47 indings, suggests that aggressive, low-grade serous carcinomas are more likely derived from serous bo

48 Because serous carcinomas are the most common EOC and account fo

49 ors (SBTs), putative precursors of low-grade serous carcinomas, are among the few human neoplasms wit

50 of the PI3K pathway, we show that high-grade serous carcinomas arise from the fallopian tube in mice.

51 found that advanced-stage, low-grade ovarian serous carcinomas both with and without adjacent serous

52 r cell carcinoma (Arid1a, Pik3ca), low-grade serous carcinoma (Braf), endometrioid (Ctnnb1), or mucin

53 en observed at high frequency in endometrial serous carcinomas but at low frequency in ovarian clear

54 Hemizygous ch1p36 deletion was common in LG serous carcinomas but was rarely seen in SBT.

55 face epithelial cell line and in a low-grade serous carcinoma cell line that expressed undetectable l

56 re, SpiD7 inhibited the growth of high-grade serous carcinoma cell lines ~3-15-fold more potently tha

57 and reduced clonogenic growth of high-grade serous carcinoma cell lines.

58 Most notable of these tumours are papillary serous carcinomas, clear-cell carcinomas, carcinosarcoma

59 r axis changes in a mouse model of oviductal serous carcinoma closely mirror those of human tubo-ovar

60 High-grade (HG) serous carcinomas contain frequent TP53 mutations, where

61 Immunohistochemistry studies in ovarian serous carcinomas demonstrate that NAC-1 is localized in

62 against i.p. chemotherapy-resistant uterine serous carcinoma-derived xenografts compared with free E

63 hat Nrf2 was highly expressed in endometrial serous carcinoma (ESC), whereas complex hyperplasia and

64 However not all cell lines derived from non-serous carcinomas exhibited similar invasive behaviour.

65 rast, none of 71 type II ovarian (high-grade serous) carcinomas exhibited PPP2R1A mutations.

66 Serous carcinoma expressed elevated levels of GC UNC-45

67 ated endometrioid, clear cell, and low-grade serous carcinomas from high-grade serous and mucinous ca

68 Our data show that the ovarian high grade serous carcinoma genome is remarkably stable between dia

69 Serous carcinoma had higher prevalence of almost all 84

70 Endometrioid and low-grade serous carcinomas had similar correlation coefficients (

71 High-grade serous carcinoma has a poor prognosis, owing primarily t

72 of deletion of tumor suppressors in ovarian serous carcinomas has not been well studied.

73 common subtype of ovarian cancer, high-grade serous carcinoma, has sparked a major effort within the

74 ust preclinical models of ovarian high-grade serous carcinoma (HGSC) are needed to advance our unders

75 High-grade serous carcinoma (HGSC) is the most prevalent and lethal

76 ch and efficacy of treatments for high-grade serous carcinoma (HGSC) of the ovary have changed little

77 g evidence indicates that ovarian high-grade serous carcinoma (HGSC) originates from fallopian tube s

78 lantable murine models of ovarian high grade serous carcinoma (HGSC) remain an important research too

79 Ovarian high-grade serous carcinoma (HGSC) results in the highest mortality

80 with advanced-stage tubo-ovarian high-grade serous carcinoma (HGSC) survive 10 or more years after s

81 High-grade serous carcinoma (HGSC) thrives in an immune-suppressive

82 umor and ascites of patients with high-grade serous carcinoma (HGSC) to uncover the metabolomes of th

83 Tumors of the high-grade serous carcinoma (HGSC) type represent the most common f

84 lantable murine models of ovarian high-grade serous carcinoma (HGSC) with regard to mutations in the

85 Ovarian high-grade serous carcinoma (HGSC), a highly aggressive cancer, mos

86 High-grade serous carcinoma (HGSC), an epithelial cancer phenotype,

87 main histopathological subtypes: high-grade serous carcinoma (HGSC), low-grade serous carcinoma (LGS

88 ctivation of FOXM1 is frequent in high-grade serous carcinoma (HGSC), the most common and lethal form

89 ocus has been detected in ovarian high-grade serous carcinoma (HGSC), the most common and malignant t

90 for patients with advanced-stage, high-grade serous carcinoma (HGSC), the most common form of ovarian

91 ailing paradigm in the genesis of high-grade serous carcinoma (HGSC), the most common ovarian cancer,

92 tube is commonly associated with high-grade serous carcinoma (HGSC), the predominant and most aggres

93 rogeneity of OC, we will focus on high-grade serous carcinoma (HGSC).

94 cantly increased risk for ovarian high-grade serous carcinoma (HGSC; 3.8% cases vs. 0.2% controls).

95 al fallopian tube among all cases.High-grade serous carcinomas (HGSCs) are associated with precursor

96 Many high-grade serous carcinomas (HGSCs) likely originate in the distal

97 Many high-grade serous carcinomas (HGSCs) of the pelvis are thought to o

98 e Atlas (TCGA), of which 169 were high-grade serous carcinomas (HGSCs).

99 f 276 women with relapsed ovarian high grade serous carcinoma in the BriTROC-1 study.

100 cent studies suggest that >50% of high-grade serous carcinomas involving the ovary likely arise from

101 in the MI frequency between endometrioid and serous carcinoma is statistically significant (P = 0.003

102 common surface epithelial tumors, low-grade serous carcinoma is the prototypic type I tumor and high

103 s the prototypic type I tumor and high-grade serous carcinoma is the prototypic type II tumor.

104 cular pathogenesis of fallopian tube-derived serous carcinomas is poorly understood and there are few

105 l cancers collectively referred to as pelvic serous carcinomas, is not well known.

106 igh-grade serous carcinoma (HGSC), low-grade serous carcinoma (LGSC), endometrioid carcinoma (EC), cl

107 profiled the DNA methylomes of 12 low-grade serous carcinomas (LGSCs), 19 SBOTs, and 16 benign serou

108 Low-grade serous carcinoma (LGSOC) of the ovary, fallopian tube, o

109 carcinoma (log-rank p<0.0001) and high-grade serous carcinoma (log-rank p=0.0006), and ER expression

110 Type II tumors include high-grade serous carcinoma, malignant mixed mesodermal tumors (car

111 Cell lines derived from non-serous carcinomas migrated more quickly and were more li

112 e tumors (SBTs), non-invasive micropapillary serous carcinomas (MPSCs), and invasive micropapillary s

113 (n = 43) but were found in 73% of high-grade serous carcinomas (n = 18).

114 rous borderline tumors (n = 30) or low-grade serous carcinomas (n = 43) but were found in 73% of high

115 onvertase, is highly expressed in high-grade serous carcinoma of ovarian cancer patients, and its exp

116 Final pathology confirmed high-grade serous carcinoma of ovarian origin ( Fig 1B ) that was d

117 Although uterine papillary serous carcinoma of the endometrium represents only 3% t

118 Low-grade serous carcinoma of the ovary (LGSOC) or peritoneum (LGS

119 Low-grade serous carcinoma of the ovary is chemoresistant but muta

120 Low-grade serous carcinoma of the ovary or peritoneum is character

121 erapy in women with stage II to IV low-grade serous carcinoma of the ovary or peritoneum.

122 tive in the treatment of recurrent low-grade serous carcinoma of the ovary or peritoneum.

123 a deep analysis of one patient with advanced serous carcinoma of the ovary.

124 Papillary serous carcinoma of the peritoneum (PSCP) is believed to

125 loss patterns on chromosome 17 to papillary serous carcinoma of the peritoneum (PSCP) which is histo

126 h a platinum- and taxane-resistant papillary serous carcinoma of the peritoneum experienced a partial

127 n tube are putative precursors to high-grade serous carcinomas of the ovary and peritoneum.

128 Uterine serous carcinoma, one of the most aggressive types of en

129 f Gynecology and Obstetrics grade 3, uterine serous carcinoma, or carcinosarcoma) categories.

130 g squamous cell carcinoma (LSCC) and ovarian serous carcinoma (OSC).

131 re common type of ovarian cancer, high-grade serous carcinoma, ovarian CCC is often resistant to plat

132 ation of chemotherapy in ovarian and uterine serous carcinoma patients by biodegradable nanoparticles

133 cated that full-length ALK expression in two serous carcinoma patients is consistent with ALK gene co

134 detected aberrant ALK expression in 2% to 4% serous carcinoma patients.

135 important role early in the pathogenesis of serous carcinoma, possibly accounting for its aggressive

136 A diagnosis of primary peritoneal serous carcinoma (PPSC) requires exclusion of a source i

137 m-resistant or refractory ovarian high-grade serous carcinoma (PR-HGSC) have a poor prognosis and few

138 ethal interactions in PP2A-deficient uterine serous carcinoma, providing potential therapeutic avenue

139 helial ovarian carcinoma (EOC) or peritoneal serous carcinoma (PSC) who had experienced disease progr

140 urrence and resistance in ovarian high grade serous carcinoma remain unclear.

141 arise via an adenoma-serous borderline tumor-serous carcinoma sequence.

142 In contrast, in HG serous carcinomas, significant numbers of amplifications

143 r involves a genetically unstable high-grade serous carcinoma that metastasizes rapidly (type II).

144 e composed, for the most part, of high-grade serous carcinomas that can be further subdivided into mo

145 Ovarian serous carcinoma, the most common and lethal type of ova

146 xpression was frequently detected in ovarian serous carcinomas, the most common and lethal type of ov

147 number alterations in 31 high-grade ovarian serous carcinomas, the most lethal gynecologic neoplasti

148 ll as a cell of origin for high-grade pelvic serous carcinomas, the need to develop tools and model s

149 cally resembled the in situ precursor of TII serous carcinomas; these lesions have not been observed

150 and ex vivo paclitaxel resistance in ovarian serous carcinoma tissues and cell lines.

151 -terminal CXCL16 was significantly higher in serous carcinoma tissues compared to endometrioid.

152 among patients with stage II to IV low-grade serous carcinoma treated with primary surgery followed b

153 In contrast, high-grade (conventional serous carcinoma) tumors contained wild-type K-ras in al

154 In addition to low-grade serous carcinomas, type I tumors are composed of mucinou

155 ll lines were derived, given that high-grade serous carcinomas typically expand and spread over perit

156 Uterine papillary serous carcinoma (UPSC) is an aggressive subtype of endo

157 Uterine serous carcinoma (USC) and uterine carcinosarcoma (UCS)

158 Uterine serous carcinoma (USC) is a biologically aggressive subt

159 Uterine serous carcinoma (USC) is a distinct histologic subtype

160 Uterine serous carcinoma (USC) is a highly aggressive endometria

161 Uterine serous carcinoma (USC) is an uncommon but aggressive typ

162 etween Black and White patients with uterine serous carcinoma (USC).

163 serous BOTs and subsequent grade 1 papillary serous carcinomas was microdissected and retrieved using

164 s containing low-grade serous and high-grade serous carcinoma were excluded.

165 In addition, copy number alterations of serous carcinomas were assessed by comparative genomic h

166 High-grade serous carcinoma, which often arises from the fallopian

167 enome-wide homozygous deletion profile in HG serous carcinomas, which can serve as a molecular founda

168 BRAF mutations in advanced-stage, low-grade serous carcinomas, which contrasts with previous finding

169 cinomas (MPSCs), and invasive micropapillary serous carcinomas, which represent a morphological conti

170 nclusion Women with stage II to IV low-grade serous carcinoma who received HMT after primary treatmen

171 trioid adenocarcinomas and uterine papillary serous carcinomas, ZEB1 could be expressed in the epithe